The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

Poor mental health was increasingly prevalent from 2011 to 2022, with inequities discernible by age, sex, and racial and ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Meanwhile, AZ is also in the ascendency thanks to a clutch of new cancer drugs that are driving buoyant sales growth. Porges also notes that the UK drugmaker’s interest in Gilead may suggest CEO ...

Caleb Avants, 26, of Shelby, is alleged to have engaged in sexual conduct and sexual contact with a juvenile over a 24-month period.

Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc (SHEL) and Gilead Sciences, Inc. (GILD).

In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The ...

Salesforce stock won an upgrade to buy from TD Cowen, which pointed to momentum for its new artificial intelligence platform.